Vivos Therapeutics, Inc.
VVOS
$2.10
-$0.04-1.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.70% | -29.74% | -36.68% | -8.02% | -35.67% |
| Total Depreciation and Amortization | 25.49% | 72.88% | 22.92% | -1.37% | 0.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -83.92% | 7.89% | 411.29% | -58.11% | -49.83% |
| Change in Net Operating Assets | -8.27% | 304.46% | -33.54% | 82.89% | -19.56% |
| Cash from Operations | -19.09% | 7.96% | -29.12% | 29.78% | -37.37% |
| Capital Expenditure | 110.77% | -531.97% | 26.06% | 14.06% | -220.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 101.41% | -4,740.98% | 26.06% | 14.06% | -220.00% |
| Total Debt Issued | -104.32% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.07% | -- | -- | -18.53% | -42.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 88.41% | -- | -- | 12.38% | -409.00% |
| Cash from Financing | -75.89% | -- | -- | -19.36% | -48.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.83% | 152.58% | -7,582.35% | 91.39% | -113.79% |